Sigma Healthcare FY26业绩强劲增长但股价当日下跌6.16%，市场关注现金转化与整合成本

Nvidia Q2 revenue more than doubles, CEO Huang says AI at its ’inflection point’
Introduction & Market Context
Sigma Healthcare (ASX:SIG) presented its FY26 results on August 27, 2026, showcasing robust financial performance following its transformational merger with Chemist Warehouse. The presentation highlighted revenue growth of 15.5% to $10.8 billion and even stronger earnings expansion, with normalized EBIT climbing 20.6% to $1.09 billion. Yet investors responded with skepticism, sending shares down 6.16% to $2.665, near the low end of the stock’s 52-week range of $2.58 to $3.20.
The disconnect between the company’s upbeat presentation and market reaction underscores investor concerns about cash conversion, integration costs, and the pace of future growth despite management’s emphasis on what it called a "structurally stronger" combined entity.
Financial Performance Highlights
As shown in the following summary of key financial metrics, Sigma delivered strong growth across all major indicators in FY26.
The company reported revenue of $10.8 billion, up 15.5% from the prior year, with normalized EBIT reaching $1.09 billion, representing 20.6% growth. Normalized net profit after tax increased 22.3% to $732.3 million, translating to earnings per share of 6.4 cents, up 21.5%. The EBIT margin expanded 43 basis points to 10.1%, demonstrating the company’s ability to convert revenue growth into faster earnings expansion.
Management emphasized that the merger has created more than just scale. "Sigma is not simply larger after the merger – it is structurally stronger," the presentation stated, pointing to improved operating leverage and a capital-light business model with a normalized return on invested capital of 19.3%.
The company declared a final dividend of 2.0 cents per share, fully franked, bringing full-year dividends to 4.0 cents and representing a 63% payout ratio. Net debt fell to $663.2 million from $752.2 million, with the net debt to normalized EBITDA ratio improving to 0.57x from 0.85x, reflecting conservative leverage.
The detailed financial breakdown shows how revenue growth translated into earnings expansion across the business.
Gross profit increased 15.2% to $1.96 billion, though gross margin held essentially flat at 18.06%, down just 5 basis points. This stability came despite the rapid growth of GLP-1 medicines, which are margin dilutive but drive customer traffic and basket size. Cost of doing business as a percentage of sales improved 47 basis points to 8.57%, demonstrating operational efficiency gains.
Segment Performance Analysis
The following breakdown illustrates the strong and consistent growth achieved across both geographical segments.
Australia remained the earnings engine, contributing 96.1% of group revenue and 94.9% of EBIT. Australian revenue grew 14.9% to $10.4 billion, while EBIT increased 18.3% to $1.03 billion, with margins expanding 28 basis points to 9.93%. The domestic business benefited from store network expansion, robust like-for-like sales growth of 13.4% in the Chemist Warehouse branded network, and operating leverage from the merger.
International operations delivered particularly impressive results, with revenue surging 33.0% to $421.4 million and EBIT nearly doubling, up 91.3% to $55.8 million. The international EBIT margin jumped 403 basis points to 13.23%, driven by scale benefits in New Zealand, improved supplier arrangements, and Ireland achieving profitability for the first time.
Operational Highlights: Four Pillars of Growth
Sigma’s presentation organized its operational achievements around four strategic pillars, each showing meaningful progress.
The domestic pillar saw the Chemist Warehouse branded network expand by 24 stores to 561 locations, generating $10.2 billion in network sales, up 15.9%. Like-for-like sales growth of 13.4% reflected strong consumer demand, store refurbishments, and GLP-1 prescription growth. Management also announced plans to reinvigorate the Amcal and Discount Drug Stores brands.
The international pillar added 20 stores, bringing the global network to 98 locations with store sales of $1.6 billion, up 23.3%. Like-for-like sales increased 12.2%, demonstrating that the Chemist Warehouse value proposition resonates across markets. The company is investing in distribution centers in Ireland and New Zealand to support continued expansion.
Product differentiation through own and exclusive label products approached $1.0 billion in sales, up 15.0%, now representing nearly 10% of Chemist Warehouse branded store sales. The company launched over 470 new products in FY26, with Wagner generic medicines achieving 88% customer adoption across the Chemist Warehouse network.
Operating leverage delivered benefits from scale, with more than 579 million units distributed, up 6.5%. The company realized $32.6 million in synergies during FY26, on track toward its $100 million annual target by FY29. Total cost per unit decreased despite absorbing increased fuel costs.
Domestic Network Expansion Strategy
The company’s ambitious domestic growth plans are illustrated in the following geographic breakdown of its pharmacy network.
Sigma operates a three-brand strategy in Australia, with Chemist Warehouse as the discount leader, Amcal+ serving community pharmacy needs, and Discount Drug Stores targeting value-conscious consumers. The presentation revealed long-term network targets of approximately 900 Chemist Warehouse stores, 300 Amcal+ locations, and 150 Discount Drug Stores, compared to current totals of 561, 194, and 86 stores respectively.
This geographic distribution shows significant expansion opportunity, particularly in Queensland and New South Wales where population growth and pharmacy penetration rates support additional stores. Management stated that 82 new Amcal and DDS stores are planned for FY27 as the brand reinvigoration gains momentum.
The Chemist Warehouse brand’s consistent performance over the past decade demonstrates the strength of its value proposition.
The brand has delivered an 11.3% compound annual growth rate in domestic sales over the past ten years, supported by both new store openings and like-for-like growth. In FY26, the company opened 24 new stores and completed 18 refurbishments, with like-for-like sales growth of 13.4% driven by product innovation, increased GLP-1 prescriptions, and the brand’s market-leading position. An Advantage Group survey recognized Chemist Warehouse as the #1 pharmacy retailer in Australia for supplier engagement, planning collaboration, and retail media effectiveness.
International Expansion Accelerating
International growth represents an increasingly important component of Sigma’s value creation strategy, as shown in the following network expansion data.
New Zealand remains the most mature international market with 75 stores at year-end, up from 61 in FY25, delivering 20.3% sales growth. Ireland, the second-largest market, expanded to 18 stores from 14, achieving 45.0% sales growth and importantly, its first profitable year. The United Arab Emirates added one store to reach three locations, while China’s network contracted to two stores as the company shifts to a profitable online-only model.
Management announced plans to enter the United Kingdom market in FY27, with two stores expected before Christmas and three more later in the fiscal year. The UK represents a significant opportunity given high pharmacy footfall and the ability to open with existing prescription volume through a joint venture model. However, executives acknowledged the UK expansion will be loss-making initially as the company builds scale.
Product Differentiation Through Own Brands
The company’s focus on own and exclusive label products provides both differentiation and a structural margin lever.
Sigma’s portfolio of own and exclusive brands now spans multiple categories, from everyday wellness products like LVL UP hydration drinks to generic medicines under the Wagner brand and supplements through Microgenics. The company sold nearly 63 million units of own and exclusive label products across the Chemist Warehouse network in FY26, with sales approaching $1.0 billion.
Management emphasized that "Chemist Warehouse is and will remain a house of brands," indicating that own-label growth complements rather than replaces national brands. The Wagner generics line achieved particularly strong penetration with 88% customer adoption, demonstrating consumer acceptance of the company’s private label pharmaceutical offerings.
Operating Leverage and Distribution Efficiency
The company’s extensive distribution network provides a foundation for continued efficiency gains.
Sigma operates 11 distribution centers across Australia with aggregate capacity exceeding 240,000 square meters, completing more than 600,000 deliveries annually. The network distributed over 579 million units to pharmacies in FY26, up 6.5%, while achieving a 2% reduction in cost per unit through route optimization, transport consolidation, and wholesale automation.
The company closed its South Guildford distribution center in Western Australia in May 2026 and plans to close the Port Adelaide facility in South Australia during the first quarter of FY27, consolidating operations to drive further efficiencies. Service levels remained strong with 99.5% delivered in full and 97.5% delivered on time. An Advantage Group supplier survey ranked Sigma as the #1 wholesaler in the fourth quarter, reflecting the quality of its distribution capabilities.
Balance Sheet Strength and Cash Flow
The company’s balance sheet reflects conservative leverage and capacity to fund growth initiatives.
Total assets increased 7.5% to $8.9 billion, with receivables up 17.5% to $1.85 billion and inventories rising 22.2% to $1.25 billion. Management attributed the inventory increase to sales growth, investment in own and exclusive label products, and the decision to bring a strategic supplier from direct-to-pharmacy distribution into the wholesale network.
Net debt declined 11.8% to $663.2 million despite the business expansion, with the net debt to normalized EBITDA ratio improving to 0.57x from 0.85x. Debt facilities were reduced to $1.4 billion with a weighted average maturity of 3.2 years while maintaining sufficient headroom for growth investments.
However, working capital management emerged as an area requiring attention. The cash conversion cycle increased from 46.9 days to 54.0 days, driven primarily by higher inventory levels. Management acknowledged this as a focus area, noting that each one-day improvement in the cash conversion cycle could release approximately $30 million in cash, with plans in place to realize these benefits.
Synergy Realization and Integration Progress
Sigma remains on track to deliver $100 million in annual synergies by FY29, having realized $32.6 million in FY26 while absorbing $25.9 million in one-off integration costs. About half of the synergies captured to date came from supply chain efficiencies, with the remainder from back-office consolidation, improved supplier terms, and procurement savings.
The company merged support centers in Preston, closed a standalone e-commerce distribution center, and consolidated the Western Australia distribution center in May 2026. The South Australia distribution center closure in early FY27 will drive additional benefits. Management is also implementing artificial intelligence across the business to enhance decision-making and drive efficiencies, while rationalizing technology systems and applications.
Outlook and Growth Priorities
Management outlined an ambitious growth agenda for FY27 and beyond, as illustrated in the following strategic priorities.
The company expects to operate a network approaching 1,000 pharmacy stores globally in the less-discretionary healthcare segment, benefiting from structural GLP-1 tailwinds. Like-for-like sales in the Australian Chemist Warehouse branded network continue to show double-digit growth in early FY27, with a trading update planned for the October annual general meeting.
For the first half of FY27, Sigma plans to open 13 Chemist Warehouse branded stores, 27 Amcal stores, and 15 Discount Drug Stores domestically, along with 19 international stores including the first UK entries. The company will continue investing in own and exclusive label products to enhance margins while capturing ongoing scale benefits and operating leverage.
Management stated it "anticipate[s] delivering double-digit revenue and earnings growth in 1H27 as we continue to execute our strategy," positioning the investment case as "a defensive and differentiated healthcare platform with a high growth earnings profile."
Market Reaction and Investor Concerns
Despite the strong operational and financial performance presented, Sigma shares fell 6.16% to $2.665 on the results announcement, trading near the low end of the 52-week range. The negative market reaction, with shares currently at $2.695, suggests investors focused on several concerns not fully addressed in the upbeat presentation.
The widening cash conversion cycle from 46.9 to 54.0 days raised questions about working capital efficiency and cash generation capacity. While management attributed this to strategic inventory investments and supplier transitions, the trend ties up capital and reduces financial flexibility.
Integration costs of $25.9 million in FY26, while declining from earlier periods, indicate the merger integration remains incomplete nearly 18 months after the transaction closed. The planned UK expansion, while strategically attractive, will generate near-term losses as the company builds scale in a new market.
Additionally, the flat gross margin of 18.1% despite strong revenue growth reflects the margin-dilutive impact of fast-growing GLP-1 medicines and competitive pressure in the Australian pharmacy market. While management emphasized the traffic and basket size benefits of GLP-1 customers, who spend approximately 40% more than non-GLP-1 customers, investors appear concerned about the sustainability of margin expansion.
The presentation’s optimistic tone and ambitious growth targets contrast with these operational challenges, potentially explaining why the market reaction diverged sharply from management’s messaging. As Sigma continues executing its merger integration and international expansion, investors will likely focus on cash conversion improvement, synergy realization, and the company’s ability to maintain margin expansion while investing in growth.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.